FibroGen
Yahoo Finance • last year
FibroGen Reports Third Quarter 2023 Financial Results
Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer Third quarter... Full story
Yahoo Finance • last year
FibroGen to Report Third Quarter 2023 Financial Results
SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also conduct a conference call on that day... Full story
Yahoo Finance • last year
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
– Study did not meet the primary endpoint – – Pamrevlumab was generally safe and well tolerated – SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Phase 3 LELANTOS-2 t... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
NEW YORK, July 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at newact... Full story
Yahoo Finance • 2 years ago
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?
On June 26, FibroGen's (NASDAQ: FGEN) lead program, pamrevlumab, reported poor late-stage clinical trial results for the second time in a month, sending its stock barreling downward to the tune of 80%. Now, shareholders have little hope th... Full story
Yahoo Finance • 2 years ago
FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug
FibroGen reported a second failure for its lead asset on Monday, and FGEN stock crashed to its lowest-ever point.... Full story
Yahoo Finance • 2 years ago
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
- Study did not meet the primary endpoint - Pamrevlumab was generally safe and well tolerated - ZEPHYRUS-2 Phase 3 study will be discontinued - Company to implement plan to extend cash runway into 2026 SAN FRANCISCO, June 26, 2023 (... Full story
Yahoo Finance • 2 years ago
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa Plan to file supplemental New Drug Application in China SAN FRANCISCO and BEIJING, May 18, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) and its subsid... Full story
Yahoo Finance • 2 years ago
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
SAN FRANCISCO, May 05, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplast... Full story
Yahoo Finance • 2 years ago
FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value
Strengthens balance sheet with significant non-dilutive capital Aligned to support FibroGen operational plan Allows for the continued advancement of pamrevlumab, as well as our pre-clinical pipelineFibroGen will receive up to $150 million... Full story
Yahoo Finance • 2 years ago
FibroGen to Report First Quarter 2023 Financial Results
SAN FRANCISCO, April 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2023 financial results on Monday, May 8 after the market close. FibroGen will also conduct a conference call on that day at 5... Full story
Yahoo Finance • 2 years ago
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
- 372 IPF Patients Enrolled - - Topline Data Anticipated Mid-2024 - SAN FRANCISCO, April 03, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the completion of patient enrollment for ZEPHYRUS-2, a Phase 3 clinical... Full story
Yahoo Finance • 2 years ago
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
FibroGen, Inc. Topline Data from Five Pivotal Phase 3 Trials in 2023 Total Company Revenue $140.7 Million in 2022 Continued Strong Roxadustat Volume Growth in China SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:... Full story
Yahoo Finance • 2 years ago
FibroGen to Present at Cowen’s 43rd Annual Health Care Conference
SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at Cowen’s 43rd Annual Health Care Conference to... Full story
Yahoo Finance • 2 years ago
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close. FibroGen will also conduct a conference c... Full story
Yahoo Finance • 2 years ago
FibroGen to Present at SVB Securities Global Biopharma Conference
SAN FRANCISCO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference... Full story
Yahoo Finance • 2 years ago
FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference
SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of America 2022 Biotech SMID Cap Virtual Confe... Full story
Yahoo Finance • 2 years ago
FibroGen Reports Third Quarter 2022 Financial Results
Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024 Completed enrollment of MATTERHORN Phase 3 study of roxadustat in patients with anemia of myelodyspl... Full story
Yahoo Finance • 2 years ago
FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management
Strengthens balance sheet with strategic non-dilutive capital to support strategic priorities Supported by global launches of EVRENZO™ in the territories partnered with Astellas Pharma Inc.FibroGen will receive $50 million in total cash up... Full story
Yahoo Finance • 2 years ago
FibroGen to Participate at Stifel 2022 Healthcare Conference
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York, NY t... Full story
